CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Year-over-year free cash flow growth rate
| Period | Value |
|---|---|
| Q4 2025 | -52.03% |
| Q3 2025 | 2.28% |
| Q2 2025 | 25.43% |
| Q1 2025 | -5.87% |
| Q4 2024 | 3.66% |
| Q3 2024 | -5.61% |
| Q2 2024 | 24.90% |
| Q1 2024 | -17.68% |
| Q4 2023 | -21.79% |
| Q3 2023 | 28.97% |
| Q2 2023 | -376.26% |
| Q1 2023 | 690.16% |
| Q4 2022 | 95.40% |
| Q3 2022 | 1.14% |
| Q2 2022 | 17.60% |
| Q1 2022 | -33.76% |
| Q4 2021 | -4.90% |
| Q3 2021 | -5.85% |
| Q2 2021 | 8.44% |
| Q1 2021 | -73.02% |
| Q4 2020 | 29.79% |
| Q3 2020 | -126.23% |
| Q2 2020 | 291.12% |
| Q1 2020 | -68.27% |
| Q4 2019 | -26.04% |
| Q3 2019 | 51.11% |
| Q2 2019 | -19.87% |
| Q1 2019 | -36.85% |
| Q4 2018 | -352.37% |
| Q3 2018 | 75.98% |
| Q2 2018 | -78.90% |
| Q1 2018 | -170.58% |
| Q4 2017 | 475.63% |
| Q3 2017 | -103.35% |
| Q2 2017 | 963.06% |
| Q1 2017 | -1601.50% |
| Q4 2016 | 108.87% |
| Q3 2016 | -197.89% |
| Q2 2016 | 361.97% |
| Q1 2016 | 29.74% |